Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Antiemetic

Therapeutic area intelligence for Antiemetic with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Companies
1

Companies

Orbit Pharma Limited →

Assets

FDA →
Orbit →

Recent signals(3)

RegulatoryJune 21, 2026

FDA Grants AP Status for Fosaprepitant Dimeglumine ANDA212143

The FDA has granted approval status (AP) for the ANDA212143 application for Fosaprepitant Dimeglumine submitted by Chia Tai Tianqing.

RegulatoryJune 19, 2026

Orbit Pharma recalls Cyclizine Lactate due to GMP deficiencies

Orbit Pharma Limited is recalling a batch of Cyclizine Lactate 50 mg/ml Solution for injection due to GMP deficiencies.

RegulatoryJune 6, 2026

FDA Submission Update for Ondansetron Hydrochloride (ANDA078127)

The FDA has received a supplemental application (ANDA078127) for Ondansetron Hydrochloride from PHARM ASSOC.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.